Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Gets Final Approval for Class Action Settlement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today said that the US District Court for the Southern District of California has approved the settlement reached in a class action suit brought by shareholders of the firm.

Under the settlement, Sequenom agreed to pay shareholders $14 million, and it agreed to issue to the plaintiffs a number of shares of Sequenom common stock.

Sequenom shareholders Leon Ries and Michelle Finlayson filed the suit against Sequenom in November on behalf of other company shareholders.

The suit, which named as defendants the company and several individual current and former executives, related to the mishandling of data surrounding SEQureDx, a non-invasive test for fetal gene and chromosome abnormalities being developed by the company.

Specifically, the plaintiffs alleged breach of fiduciary duties against a number of current and ex-officials, and leveled charges of insider stock trading against a former official who allegedly sold more than 22,000 shares of his personally held Sequenom stock just prior to the company issuing a press release last April detailing the data mishandling.

News of the data mishandling, which followed some 14 instances of the company allegedly providing false information such as positive scientific data about the progress of the test, caused Sequenom's stock price to plunge to $3.62 per share from $14.91 per share, an approximate market capitalization loss of $687 million, according to the suit.

Shares of Sequenom were down 3 percent at $5.82 in early Wednesday trade on the Nasdaq.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.